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We have read with great interest the article entitled ‘‘Surgical
workload, risk factors and complications in patients on warfarin
with gastrointestinal bleeding’’ by Som et al. which has been
published online in International Journal of Surgery.1 The authors
aimed to determine the predisposing factors which cause gastro-
intestinal system (GIS) bleeding among patients using warfarin.
We would like to comment on the article by referring to our
study on predisposing preventable factors among patients
admitted to the emergency department with bleeding due to
warfarin usage.2 Som et al. evaluated 30 patients with a mean
age of 80 years (range 63–93) who had admitted to the hospital
with GIS bleeding during the period of warfarin use while we
have evaluated 114 cases who admitted to emergency service
with bleeding due to warfarin usage. The mean age of the our
patients was 66.65  13.57 years (mean  standard deviation
[SD], 27–89 years, 82 cases 60 years) and 61 (53.5%) of them
were females. Among 45 of our patients GIS bleeding was present
at the time of admission. Melena was the most frequent type of
bleeding (42/114 patients, 36.4%) followed by hematemesis (13/
114 patients, 11.4%), and hematochezia was present in two of
the cases (2/114 patients, 1.6%). Among the patients who
admitted to the emergency service, 37 had described bleeding
history formerly; of which 15 (15/37 patients, 40.5%) were GIS
bleeding. Indication of treatment with warfarin was chronic atrial
ﬁbrillation in 32 cases (28.1%), heart valve replacement in 27
cases (23.7%), cerebrovascular event in 26 cases (22.8%), venous
thrombosis and/or pulmonary embolism in 24 cases (21.0%),
and peripheral arterial embolism in ﬁve cases. The mean number
of the drugs being used other than warfarin was 4.8  2.5 drugs
(mean  SD; 0–14; median four drugs). One hundred twelve of
the cases (98.2%) were using at least one drug other than
warfarin at the time of admission to the emergency service
with bleeding. The number of the drugs being used which are
known to effect warfarin metabolism was 1.7  1.3 (0–6; median
1.5 drugs). Ninety ﬁve (83.3%) of these patients were using atiates Ltd. Published by Elsevier Ltleast one drug, which is known to effect warfarin metabolism
at the time of admission; 48 cases (42.1%) were using aspirin,
28 (24.6%) non-steroidal anti-inﬂammatory drugs (NSAID) other
than aspirin, and 18 cases (15.8%) were using various antibiotics.
Two of the cases were using more than one NSAID. Thirty ﬁve of
the patients (30.7%) were using these analgesics without
prescription of a physician (in six of these cases, the drug was
aspirin, in 12 cases NSAIDs). Three patients were using enoxa-
parin, ﬁve clopidogrel, and two dipyridamole. Som et al. have
reported that the age of the patient was another important risk
factor besides polypharmacy. In our study we did not ﬁnd a statis-
tically signiﬁcant difference between the weekly warfarin doses
used by the 82 cases who are 60 years and the 32 cases who
are <60 years (30.1  10.4 mg/week and 33.9  11.9 mg/week,
respectively; p ¼ 0.107). Similarly the duration between the
warfarin onset and the time of bleeding was not signiﬁcantly
different between these age groups (28.7  43.3 months and
39.1  61.3 months, respectively; p ¼ 0.387). The frequency of
bleeding within the ﬁrst month and the 6 months of warfarin
treatment among the patients 60 years and <60 years were
not statistically different (ﬁrst month; 26/82 and 8/32 cases,
respectively; p ¼ 0.634; 6 months period; 35/82 and 14/32 cases,
respectively; p ¼ 0.915). We also determined that forty eight of
the patients (42.1%) knew that they had to use this drug under
the regular follow-up of a physician and 43 (37.7%) knew that
during monitoring a laboratory test had to be done while using
the drug named as warfarin. Only 39 patients (34.2%) knew this
drug may cause bleeding. It was also surprising that only nine
of the patients knew that there may be an interaction with
concomitant drugs and one knew that this drug may be affected
from the dietary factors. As a result, our patients who admitted to
the emergency service with bleeding have a lack of knowledge
which invited bleeding. Both studies indicate that most patients
were using drugs which are known to interact with warfarin
metabolism while using warfarin. We would like to emphasize
that physicians should inform their patients about the possible
interaction of warfarin with other drugs, particularly given thed. All rights reserved.
Letter to the Editor / International Journal of Surgery 8 (2010) 257–258258easy access to analgesics without a prescription. It is therefore
vital that physicians, when performing periodic examinations of
patients on warfarin, remind these patients about the interaction
between warfarin and other drugs.
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